Phase I study of the aurora kinases (AKs) inhibitor PHA-739358 administered as a 6 and 3-h IV infusion on Days 1, 8, 15 every 4 wks in patients with advanced solid tumors

Authors :: M. Rocchetti
H. Gelderblom
Jaap Verweij
Jan Ouwerkerk
F. Eskens
M.J.A. de Jonge
Neeltje Steeghs
B. Laffranchi
J.W.R. Nortier
Mariangela Mariani
Source :: Journal of Clinical Oncology. 26:3507-3507
Publication Year :: 2008
Publisher :: American Society of Clinical Oncology (ASCO), 2008.
Abstract: 3507 Background: Aurora proteins belong to a family of serine/threonine kinases that are key regulators of different steps in mitosis. AKs were found to be implicated in tumorigenesis and overexpre...

Subjects :: Cancer Research
business.industry
Kinase
Pharmacology
medicine.disease_cause
Phase i study
Serine
Oncology
Immunology
Medicine
In patient
Threonine
business
Carcinogenesis
PHA-739358
Mitosis

Full Text Access

Tools